Lucosky Brookman LLP represented Konik Capital Partners in its $50 million dollar PIPE transaction for Kazia Therapeutics Limited, an oncology-focused drug development company advancing innovative cancer therapies.
This significant capital infusion will support the company’s continued clinical development efforts of its lead program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer.
